Las Vegas, NV -- (SBWIRE) -- 01/23/2013 -- PennyStockParlay.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
European regulators said on Tuesday that they still have some questions pertaining to Arena Pharmaceuticals, Inc.(NASDAQ:ARNA)’s weight-loss drug Belviq.
Should Investors Buy ARNA After The Recent Drop? Find Out Here
It sent the shares of the company down 1.8 percent to $8.66 at the end of the trading day.
Arena said in a statement that a committee that advises the European Medicines Agency is asking for more information about Belviq, including heart valve issues and psychiatric side effects as well as tumors that were observed during studies on rats. The advisory panel also asked the company to justify the risks and benefits that Belviq offers.
The U.S. Food and Drug Administration had approved Belviq in late June and Arena had planned to start selling the drug in the United States soon with its partner Eisai.
Arena is expecting the European authorities to approve the drug in the first half of 2013, as it is working to win marketing clearance by addressing the concerns raised by them.
Synovus Financial Corp. (NYSE:SNV) got a boost in its profit for the fourth quarter from an income tax benefit.
We Have A Free Trend Analysis on SNV, Find Out Here
Synovus reported net income of $712.8 million, or 78 cents per share, for the quarter that ended Dec. 31. That is compared with net income of $12.8 million, or 1 cent per share, in the same quarter of the prior year.
That included an $800 million income tax benefit as the company recaptured substantially all of its deferred tax asset valuation allowance.
The company's net interest income, or money earned from deposits and loans, fell 8.7 percent to $207.5 million. Analysts were expecting $216.5 million. Its noninterest income, money earned from fees, charges and other sources, increased 9 percent to $80.1 million.
Shares in Synovus closed down at $2.56 at the end of the trading session.
PennyStockParlay.com has been successful in bringing Stock Parlay members with top penny stock newsletter. Stock Parlay’s staff and penny stocks exploration methods have proved 100% accurate in finding the best penny stocks move in e-mail alerts. PennyStockParlay.com works all day and night to find the best penny stock picks portfolio through penny stock newsletter. PennyStockParlay.com has kept winning members with top penny stock newsletter.
The assembled information disseminated by PennyStockParlay.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. PennyStockParlay.com does expect that investors will buy and sell securities based on information assembled and presented in PennyStockParlay.com. Please always do due diligence; consult a financial advisor before buying or selling stocks.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)